AGEN Investors Have Opportunity to Lead Agenus Inc. Securities Fraud Lawsuit

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Agenus Inc. securities, alleging that the company made false and misleading statements regarding its drug therapies during the specified Class Period [1][4]. Group 1: Lawsuit Details - The class action lawsuit pertains to securities purchased between January 23, 2023, and July 17, 2024, inclusive [1]. - The lawsuit claims that Agenus misrepresented the effectiveness of its combination therapy involving botensilimab and balstilimab, leading to overstated clinical results and commercial prospects [4]. - Investors are encouraged to join the class action, with the deadline to serve as lead plaintiff set for November 5, 2024 [1][2]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm specializes in securities class actions and has a strong track record, including the largest securities class action settlement against a Chinese company [3]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions for investors, including over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen has been recognized as a leading figure in the plaintiffs' bar, enhancing the firm's credibility [3].